Clinical features, myocardial strain and tissue characteristics of heart failure with preserved ejection fraction in patients with obesity: A prospective cohort study

Towards Phenotyping Characteristics and Mechanism of Conduction Delay in Patients With Nonischemic Heart Failure With Reduced Ejection Fraction: Insights From Cardiac Magnetic Resonance Imaging

BACKGROUND

Considering that 30% to 40% of patients do not benefit from cardiac resynchronization therapy implantation, it is insufficient to evaluate patients with heart failure with reduced ejection fraction solely based on QRS duration and morphology for guiding cardiac resynchronization therapy decisions and prognosis. A crucial step in addressing this issue is conducting a comprehensive pathophysiological assessment to understand the mechanisms underlying dyssynchrony and inefficient cardiac contraction. This study aims to utilize cardiac magnetic resonance imaging to explore underlying pathophysiological impairments in patients with heart failure with reduced ejection fraction with different QRS morphologies, seeking to identify better indicators for clinical assessment.

METHODS

A retrospective analysis was conducted on 887 consecutive patients with nonischemic heart failure with reduced ejection fraction and prolonged QRS duration who underwent cardiac magnetic resonance imaging, as well as 200 subjects with heart failure with reduced ejection fraction and normal QRS duration as the control group.

RESULTS

Patients with left bundle-branch block (LBBB) had a reduced left ventricular/right ventricular ejection fraction ratio compared with controls and patients with right bundle- branch block (RBBB) (LBBB versus RBBB versus controls: 0.6 [0.5, 0.8] versus 0.8 [0.6, 1.1] versus 0.8 [0.6, 1.1]). Late gadolinium enhancement percentage and extracellular volume fraction were significantly larger in patients with RBBB and nonspecific intraventricular conduction delay than in controls and patients with LBBB. Patients with LBBB or intraventricular conduction delay were associated with more impaired left ventricular torsion (LBBB versus intraventricular conduction delay versus RBBB: 0.3°/cm [-0.3, 0.5] versus 0.4°/cm [0.2, 0.7] versus 0.5°/cm [0.2, 0.8]) and strains than those with RBBB. Multivariable logistic regression revealed that the left ventricular/right ventricular ejection fraction ratio and torsion were independent determinants of LBBB.

CONCLUSIONS

A reduced left ventricular/right ventricular ejection fraction ratio and impaired left ventricular torsion may serve as valuable predictors of dyssynchrony, potentially identifying patients most likely to benefit from cardiac resynchronization therapy.

[A cardiac magnetic resonance-based risk prediction model for left ventricular adverse remodeling following percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: a multi-center prospective study]

OBJECTIVES

To develop a risk prediction model for left ventricular adverse remodeling (LVAR) based on cardiac magnetic resonance (CMR) parameters in patients undergoing percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI).

METHODS

A total of 329 acute STEMI patients undergoing primary PCI at 8 medical centers from January, 2018 to December, 2021 were prospectively enrolled. The parameters of CMR, performed at 7±2 days and 6 months post-PCI, were analyzed using CVI42 software. LVAR was defined as an increase >20% in left ventricular end-diastolic volume or >15% in left ventricular end-systolic volume at 6 months compared to baseline. The patients were randomized into training (n=230) and validation (n=99) sets in a 7∶3 ratio. In the training set, potential predictors were selected using LASSO regression, followed by univariate and multivariate logistic regression to construct a nomogram. Model performance was evaluated using receiver-operating characteristic (ROC) curves, area under the curve (AUC), calibration curves, and decision curve analysis.

RESULTS

LVAR occurred in 100 patients (30.40%), who had a higher incidence of major adverse cardiovascular events than those without LVAR (58.00% vs 16.16%, P<0.001). Left ventricular global longitudinal strain (LVGLS; OR=0.76, 95% CI: 0.61-0.95, P=0.015) and left atrial active strain (LAAS; OR=0.78, 95% CI: 0.67-0.92, P=0.003) were protective factors for LVAR, while infarct size (IS; OR=1.05, 95% CI: 1.01-1.10, P=0.017) and microvascular obstruction (MVO; OR=1.26, 95% CI: 1.01-1.59, P=0.048) were risk factors for LVAR. The nomogram had an AUC of 0.90 (95% CI: 0.86-0.94) in the training set and an AUC of 0.88 (95% CI: 0.81-0.94) in the validation set.

CONCLUSIONS

LVGLS, LAAS, IS, and MVO are independent predictors of LVAR in STEMI patients following PCI. The constructed nomogram has a strong predictive ability to provide assistance for management and early intervention of LVAR.

Echocardiographic Assessment of Cardiac Remodeling According to Obesity Class

Evidence supports the existence of cardiac remodeling in obesity; however, no standard diagnostic criteria has been proposed or validated. This study aimed to identify echocardiographic features of cardiac remodeling according to obesity class and assess the effect of nonsurgical weight loss on cardiac structure and function. A total of 120 patients were divided according to their obesity class (group 1: body mass index [BMI] 18.5 to 24.9, group 2: 25 to 29.9, group 3: 30 to 39.9, and group 4: >40) and underwent cross-sectional transthoracic echocardiography. Echocardiographic parameters of cardiac chamber quantification and function were compared among the 4 groups. Echocardiographic parameters were compared before and after nonsurgical weight loss in a subgroup of patients. Overall, there was an incremental increase in left ventricular (LV), left atrial (LA), and right ventricular dimensions, LV mass (LVM), and LV stroke volume (all p <0.0001) across the obesity classes. There was no significant difference in LV ejection fraction or right ventricular systolic function, as assessed by tricuspid annular plane systolic excursion; however, there was a significant decrease in global longitudinal strain (BMI 18.5 to 24.9: 22.8 ± 1.7%, BMI 25 to 29.9: 22.0 ± 1.4%, BMI 30 to 39.9: 20.8 ± 1.1%, BMI >40: 20.6 ± 1.3%, p <0.0001) and LA strain (BMI 18.5 to 24.9: 37.7 ± 2.3%, BMI 25 to 29.9: 32.8 ± 2.1%, BMI 30 to 39.9: 31.5 ± 1.8%, BMI >40: 29.0 ± 2.8%, p <0.0001). Allometric height-indexed LV and LA dimensions increased with increasing BMI class (p <0.0001). Echocardiographic parameters did not change significantly after nonsurgical weight loss. In conclusion, echocardiographic features can be described according to obesity class. Allometric height indexation may better reflect cardiac remodeling in obesity than body surface area indexation. Nonsurgical weight loss was not associated with significant changes in cardiac chamber dimensions and function.

Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with various phenotypes, and obesity is one of the most common and clinically relevant phenotypes of HFpEF. Obesity contributes to HFpEF through multiple mechanisms, including sodium retention, neurohormonal dysregulation, altered energy substrate metabolism, expansion of visceral adipose tissue, and low-grade systemic inflammation. Glucagon-like peptide-1 (GLP-1) is a hormone in the incretin family. It is produced by specialized cells called neuroendocrine L cells located in the distal ileum and colon. GLP-1 reduces blood glucose levels by promoting glucose-dependent insulin secretion from pancreatic β cells, suppressing glucagon release from pancreatic α cells, and blocking hepatic gluconeogenesis. Recent evidence suggests that GLP-1 receptor agonists (GLP-1 RAs) can significantly improve physical activity limitations and exercise capacity in obese patients with HFpEF. The possible cardioprotective mechanisms of GLP-1 RAs include reducing epicardial fat tissue thickness, preventing activation of the renin-angiotensin-aldosterone system, improving myocardial energy metabolism, reducing systemic inflammation and cardiac oxidative stress, and delaying the progression of atherosclerosis. This review examines the impact of obesity on the underlying mechanisms of HFpEF, summarizes the trial data on cardiovascular outcomes of GLP-1 RAs in patients with type 2 diabetes mellitus, and highlights the potential cardioprotective mechanisms of GLP-1 RAs to give a pathophysiological and clinical rationale for using GLP-1 RAs in obese HFpEF patients.

Myocardial Abnormalities Across the AHA/ACC Stages of Heart Failure in Patients With Diabetes

Background

Cardiac magnetic resonance imaging (CMR) could serve as a robust tool for comprehensive evaluation of early changes across heart failure (HF) stages classified by the American Heart Association/American College of Cardiology guideline in diabetes mellitus (DM).

Objectives

The authors aimed to explore phenotypic imaging features characterizing DM participants at different HF stages by CMR.

Methods

DM participants with preserved ejection fraction who underwent CMR examination between January 2020 and December 2021 were evaluated. Left ventricular strain analysis and myocardial fibrosis was evaluated by CMR.

Results

A total of four hundred seventy-five DM participants at different HF stages (mean age 56 ± 12 years; 326 men) and 78 healthy control subjects were evaluated. Significantly decreased absolute strain values with rising HF stage were identified in DM. In addition, early diastolic strain rates were significantly lower in stage B and C HF than in stage A HF and control subjects. Myocardial extracellular volume increased with advancing HF stage in DM (stage A, 27.0% ± 2.9%; stage B, 29.1% ± 3.5%; stage C, 30.5% ± 4.1%; P < 0.05). In multivariable logistic regression analysis, early diastolic longitudinal strain rate (OR: 2.184; 95% CI: 1.378-3.461; P < 0.001) was a significant contributor that independently distinguished DM participants at stage A from control subjects, with an area under the receiver-operating characteristic curve of 0.726. For global longitudinal strain and extracellular volume, each 1% increase was associated with 1.333 and 1.300 times adjusted odds of diagnosis of stage B HF (both P < 0.05).

Conclusions

Subclinical dysfunction and myocardial fibrosis derived from CMR were progressively remarkable with advancing HF stage in DM. Comprehensive CMR provided sensitive tools for better delineation of DM patients with pre-HF and at risk for HF.

[Left Ventricular Structural and Functional Changes in Obese Subjects With Preserved Left Ventricular Ejection Fraction After Bariatric Surgery: Assessment With Cardiac Magnetic Resonance Imaging]

Objective

To investigate the longitudinal changes in left ventricular (LV) structure and function after bariatric surgery in obese individuals and their relationship with preoperative left ventricular ejection fraction (LVEF) by cardiac magnetic resonance (CMR) imaging.

Methods

We prospectively enrolled 75 obese subjects scheduled for laparoscopic sleeve gastrectomy and 46 age and sex-matched healthy controls (the control group). All subjects underwent CMR examination to obtain LV structural parameters, LVEF, and strain parameters. According to their preoperative LVEF, the obese subjects were divided into two obesity groups, including the group of patients with LVEF≥60% (n=43) and the group of patients with 50%≤LVEF<60% (n=32). LV structural and functional differences between the control group and the two obesity groups were compared. Eventually, 38 obese subjects completed the CMR follow-up at 1 month and 12 months after bariatric surgery. The longitudinal changes in LV structure and function after surgery in the LVEF≥60% (n=20) group and the 50%≤LVEF<60% group (n=18) were compared.

Results

Before bariatric surgery, the global longitudinal strain was significantly lower in the LVEF≥60% group than that in the control group ([－18.36±1.86]% vs. [－19.50±1.53]%, P<0.05). The global radial ([27.70±3.52]% vs. [34.44±4.11]%, P<0.05), circumferential ([－17.35±1.46]% vs. [－19.85±1.42]%, P<0.05), and longitudinal ([－16.22±1.81]% vs. [－19.50±1.53]%, P<0.05) strain in the 50%≤LVEF<60% group was significantly lower than that in the control group. At 12 months after bariatric surgery, the global radial ([32.52±7.84]% vs. [30.92±4.27]%, P>0.05), circumferential ([－19.02±2.42]% vs. [－18.63±1.49]%, P>0.05), and longitudinal ([－18.18±2.06]% vs. [－17.78±1.66]%, P>0.05) strain in the LVEF≥60% group showed no significant difference compared with the baseline findings. In the 50%≤LVEF<60% group, the global radial ([32.73±5.86]% vs. [26.83±4.85]%, P<0.05) and circumferential ([－19.10±2.00]% vs. [－16.91±2.09]%, P<0.05) strain was significantly higher than that before surgery.

Conclusion

LV remodeling is reversed after bariatric surgery in obese subjects, and the longitudinal changes in LV structure and function vary with the preoperative LVEF.

The transition from hypertension to hypertensive heart disease and heart failure with preserved ejection fraction: a retrospective cross-sectional study of myocardial magnetic resonance strain and tissue characteristics

Background

Due to the variability of symptoms and signs associated with heart failure, along with the lack of specific tests for definitive diagnosis, the noninvasive diagnosis of heart failure with preserved ejection fraction (HFpEF) continues to pose significant clinical challenges. This investigation was designed to elucidate the clinical manifestations of HFpEF and to analyze cardiac magnetic resonance (CMR)-derived myocardial strain metrics and tissue characteristics in a cohort exhibiting HFpEF with hypertension (HFpEF-HTN).

Methods

This retrospective analysis consisted of 128 patients diagnosed HFpEF-HTN, 78 individuals with hypertensive heart disease (HHD), 89 individuals with hypertension (HTN), and 60 normotensive healthy controls and was conducted from August 2021 to February 2024. All participants were recruited from The First Hospital of Lanzhou University and underwent laboratory examinations and 3.0 T CMR. The study compared clinical features and CMR-derived structural and functional parameters across different groups. Logistic regression was employed to determine the association between CMR parameters and HFpEF-HTN. Spearman correlation coefficient analysis was used to clarify the relationship between myocardial strain parameters and left ventricular (LV) ejection fraction and right ventricular (RV) ejection fraction. Additionally, the area under the curve (AUC) from receiver operating characteristic (ROC) analysis was used to compare the diagnostic performance of different CMR parameters for HFpEF-HTN.

Results

Patients diagnosed with (HFpEF-HTN) were characterized by an older demographic profile, a higher prevalence of smoking history, elevated systolic and diastolic blood pressure, increased levels of N-terminal pro-brain natriuretic peptide, and more advanced New York Heart Association functional class as compared to other studied groups. In terms of myocardial deformation, individuals with HFpEF-HTN exhibited pronounced impairments in both LV and RV function, as evidenced by significantly reduced longitudinal strain (LS), circumferential strain (CS), and radial strain (RS), relative to HTN, HHD, the control cohorts (all P values <0.001). Patients with HFpEF-HTN showed significantly elevated levels of late gadolinium enhancement, native T1, and extracellular volume fraction (ECV) indicative of myocardial interstitial fibrosis as compared to patients with HHD. Additionally, as compared to ECV, LV GCS emerged as a superior diagnostic indicator, demonstrating greater diagnostic accuracy in differentiating HFpEF-HTN patients from those with HHD (AUC =0.85; P<0.001). Moreover, LVEF showed a mild correlation with CMR-derived LV GLS (R=-0.43; P<0.001), LV GCS (R=-0.42; P<0.001), and LV GRS, (R=0.56; P<0.001) in all patients.

Conclusions

Myocardial strain, T1 mapping, and ECV can be used for the quantitative evaluation of LV and RV ventricular remodeling, dysfunction, and tissue characteristics in patients with HFpEF-HTN and thus hold significant potential for the diagnosis of these patients.

Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations

Heart failure with preserved ejection fraction (HFpEF) refers to a clinical condition in which the signs of heart failure, such as pulmonary congestion, peripheral edema, and increased natriuretic peptide levels, are present despite normal ejection fractions and the absence of other causes (eg, pericardial disease). The ejection fraction cutoff for the definition of HFpEF has varied in the past, but recent society guidelines have settled on a consensus of 50%. HFpEF is particularly common in the elderly population. The aim of this narrative review is to summarize the available literature regarding HFpEF in elderly patients in terms of evidence for the age dependence, specific clinical features, and underlying mechanisms. In the clinical arena, we review the epidemiology, discuss distinct clinical phenotypes typically seen in elderly patients, the importance of frailty, the role of biomarkers, and the role of medical therapies (including sodium-glucose cotransport protein 2 inhibitors, renin-angiotensin-aldosterone system blockers, angiotensin receptor/neprilysin inhibitors, diuretics, and β-adrenergic receptor blockers). We then go on to discuss the basic mechanisms implicated in HFpEF, including cellular senescence, fibrosis, inflammation, mitochondrial dysfunction, enhanced production of reactive oxygen species, abnormal cellular calcium handling, changes in microRNA signalling, insulin resistance, and sex hormone changes. Finally, we review knowledge gaps and promising areas of future investigation. Improved understanding of the specific clinical manifestations of HFpEF in elderly individuals and of the fundamental mechanisms that contribute to the age-related risk of HFpEF promises to lead to novel diagnostic and treatment approaches that will improve outcomes for this common cardiac disorder in a vulnerable population.

Heart Failure with Normal Natriuretic Peptide Levels and Preserved Ejection Fraction: A Prospective Clinical and Cardiac MRI Study

Purpose To describe the clinical presentation, comprehensive cardiac MRI characteristics, and prognosis of individuals with predisposed heart failure with preserved ejection fraction (HFpEF). Materials and Methods This prospective cohort study (part of MISSION-HFpEF [Multimodality Imaging in the Screening, Diagnosis, and Risk Stratification of HFpEF]; NCT04603404) was conducted from January 1, 2019, to September 30, 2021, and included individuals with suspected HFpEF who underwent cardiac MRI. Participants who had primary cardiomyopathy and primary valvular heart disease were excluded. Participants were split into a predisposed HFpEF group, defined as HFpEF with normal natriuretic peptide levels based on an HFA-PEFF (Heart Failure Association Pretest Assessment, Echocardiography and Natriuretic Peptide, Functional Testing, and Final Etiology) score of 4 from the latest European Society of Cardiology guidelines, and an HFpEF group (HFA-PEFF score of ≥ 5). An asymptomatic control group without heart failure was also included. Clinical and cardiac MRI-based characteristics and outcomes were compared between groups. The primary end points were death, heart failure hospitalization, or stroke. Results A total of 213 participants with HFpEF, 151 participants with predisposed HFpEF, and 100 participants in the control group were analyzed. Compared with the control group, participants with predisposed HFpEF had worse left ventricular remodeling and function and higher systemic inflammation. Compared with participants with HFpEF, those with predisposed HFpEF, whether obese or not, were younger and had higher plasma volume, lower prevalence of atrial fibrillation, lower left atrial volume index, and less impaired left ventricular global longitudinal strain (-12.2% ± 2.8 vs -13.9% ± 3.1; P < .001) and early-diastolic global longitudinal strain rate (eGLSR, 0.52/sec ± 0.20 vs 0.57/sec ± 0.15; P = .03) but similar prognosis. Atrial fibrillation occurrence (hazard ratio [HR] = 3.90; P = .009), hemoglobin level (HR = 0.94; P = .001), and eGLSR (per 0.2-per-second increase, HR = 0.28; P = .002) were independently associated with occurrence of primary end points in participants with predisposed HFpEF. Conclusion Participants with predisposed HFpEF showed relatively unique clinical and cardiac MRI features, warranting greater clinical attention. eGLSR should be considered as a prognostic factor in participants with predisposed HFpEF. Keywords: Heart Failure with Preserved Ejection Fraction, Normal Natriuretic Peptide Levels, Cardiovascular Magnetic Resonance, Myocardial Strain, Prognosis Clinical trial registration no. NCT04603404 Supplemental material is available for this article. © RSNA, 2024.

Sudden Cardiac Death Risk Stratification in Heart Failure With Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) poses a significant clinical challenge, with sudden cardiac death (SCD) emerging as one of the leading causes of mortality. Despite advancements in cardiovascular medicine, predicting and preventing SCD in HFpEF remains complex due to multifactorial pathophysiological mechanisms and patient heterogeneity. Unlike heart failure with reduced ejection fraction, where impaired contractility and ventricular remodeling predominate, HFpEF pathophysiology involves heavy burden of comorbidities such as hypertension, obesity, and diabetes. Diverse mechanisms, including diastolic dysfunction, microvascular abnormalities, and inflammation, also contribute to distinct disease and SCD risk profiles. Various parameters such as clinical factors and electrocardiogram features have been proposed in SCD risk assessment. Advanced imaging modalities and biomarkers offer promise in risk prediction, yet comprehensive risk stratification models specific to HFpEF ar0e lacking. This review offers recent evidence on SCD risk factors and discusses current therapeutic strategies aimed at reducing SCD risk in HFpEF.

The link between obesity and aging - insights into cardiac energy metabolism

Obesity and aging are well-established risk factors for a range of diseases, including cardiovascular diseases and type 2 diabetes. Given the escalating prevalence of obesity, the aging population, and the subsequent increase in cardiovascular diseases, it is crucial to investigate the underlying mechanisms involved. Both aging and obesity have profound effects on the energy metabolism through various mechanisms, including metabolic inflexibility, altered substrate utilization for energy production, deregulated nutrient sensing, and mitochondrial dysfunction. In this review, we aim to present and discuss the hypothesis that obesity, due to its similarity in changes observed in the aging heart, may accelerate the process of cardiac aging and exacerbate the clinical outcomes of elderly individuals with obesity.